Track Rigel Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Rigel Pharmaceuticals, Inc. RIGL Open Rigel Pharmaceuticals, Inc. in new tab

27.53 USD
P/E
1.32
EPS
19.48
P/B
1.21
ROE
185.94
Beta
1.17
Target Price
51.20 USD
Rigel Pharmaceuticals, Inc. logo

Rigel Pharmaceuticals, Inc.

🧾 Earnings Recap – Q3 2025

Rigel Pharmaceuticals reported robust financial performance in Q3 2025, achieving record net product sales of $64.1 million, a 65% year-over-year increase, alongside significant advancements in its development pipeline.

  • Total revenue for Q3 2025 reached $69.5 million, reinforcing strong commercial execution and strategic pipeline expansion.
  • The company raised its 2025 revenue guidance to a range of $285 million to $290 million, reflecting a growth of 55% to 59% compared to 2024.
  • Rigel achieved net income of $27.9 million in Q3 and increased cash reserves to $137.1 million, maintaining strong financial discipline.
  • Key products TAVALISSE, GAVRETO, and REZLIDHIA all demonstrated substantial year-over-year growth, with TAVALISSE alone generating $44.7 million in net sales.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 4, 2026
P/E1.32
EPS19.48
Book Value21.38
Price to Book1.21
Debt/Equity13.62
% Insiders3.102%
Growth
Revenue Growth0.21%
Earnings Growth15.99%
Estimates
Forward P/E5.38
Forward EPS4.80
Target Mean Price51.20

DCF Valuation

Tweak assumptions to recompute fair value for Rigel Pharmaceuticals, Inc. (RIGL)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Rigel Pharmaceuticals, Inc. Logo Rigel Pharmaceuticals, Inc. Analysis (RIGL)

United States Health Care Official Website Stock

Is Rigel Pharmaceuticals, Inc. a good investment? Rigel Pharmaceuticals, Inc. (RIGL) is currently trading at 27.53 USD. Market analysts have a consensus price target of 51.20 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 1.32. This relatively low multiple may signal that Rigel Pharmaceuticals, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Rigel Pharmaceuticals, Inc. is expected to release its next earnings report on May 4, 2026. The market consensus estimate for Forward EPS is 4.80.

Investor FAQ

Does Rigel Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Rigel Pharmaceuticals, Inc.?

Rigel Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 4, 2026. The company currently has a trailing EPS of 19.48.

Company Profile

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Exchange Ticker
NMS (United States) RIGL
FRA (Germany) RI2A.F

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
June 25, 2003 0.110000
June 27, 2024 0.100000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion